期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
细菌多重耐药泵的研究进展 被引量:14
1
作者 王春梅 何启盖 操继跃 《畜牧兽医学报》 CAS CSCD 北大核心 2011年第4期455-467,共13页
细菌主要通过药物代谢酶将药物失活、靶向改造药物作用部位、降低细胞膜通透性和通过耐药泵主动将胞内药物泵出胞外4种方式抵抗抗生素和其他药物的毒性作用,其中细菌通过耐药泵将药物排出胞外是细菌的主要耐药机制之一,尤其是多重耐药泵... 细菌主要通过药物代谢酶将药物失活、靶向改造药物作用部位、降低细胞膜通透性和通过耐药泵主动将胞内药物泵出胞外4种方式抵抗抗生素和其他药物的毒性作用,其中细菌通过耐药泵将药物排出胞外是细菌的主要耐药机制之一,尤其是多重耐药泵,可以外排结构迥异的多种药物或对细菌有毒的代谢产物。由于细胞膜结构的不同,革兰氏阴性菌和革兰氏阳性菌所具有的耐药泵种类和结构也有所不同。革兰氏阴性菌中,目前发现的细菌耐药泵种类主要包括ATP结合盒超家族(ATP-binding cassette family,ABC)、耐药节结化细胞分化(resistancenodulation division,RND)家族、主要易化子超家族(major facilitator superfamily,MFS)、小多重耐药(small multi-drug resistance,SMR)家族和多药及毒性化合物外排家族(multidrug and toxic-compound extrusion family,MA-TE)。革兰氏阳性菌中,目前发现的细菌耐药泵种类主要包括ABC、MFS、SMR和MATE家族。近年来,诸多学者开展了细菌耐药泵的结构及其耐药机制的研究,并且已有新药研发团队以绿脓杆菌耐药泵MexAB-OprM的结构为作用靶点开发新的抗菌药物做了大量的探索工作,天然化合物和常规药物中也存在能够抑制耐药泵活性的化合物。作者主要针对耐药泵的分类、不同细菌中耐药泵的特征及耐药泵作为新药作用靶点的潜在应用价值进行综述。 展开更多
关键词 细菌 多重 耐药泵抑制剂
下载PDF
细菌的多药耐药外排泵 被引量:2
2
作者 刘茜醇 王丹 +2 位作者 何亚峰 陈未中 陈浩 《药物生物技术》 CAS 2013年第2期175-178,共4页
由于抗生素药物的不合理使用等原因,病原微生物耐药性问题日益突出,严重影响了细菌性感染疾病的治疗效果,也逐渐成为目前人类着重关注的健康问题。微生物可通过多种方式来抵御抗生素引起的毒性,其中利用耐药泵将药物直接外排的方式是细... 由于抗生素药物的不合理使用等原因,病原微生物耐药性问题日益突出,严重影响了细菌性感染疾病的治疗效果,也逐渐成为目前人类着重关注的健康问题。微生物可通过多种方式来抵御抗生素引起的毒性,其中利用耐药泵将药物直接外排的方式是细菌主要的耐药性机制之一。通过对耐药泵结构和机制的研究,有利于开发以多药耐药泵为作用靶点的细菌敏感型药物,对于降低细菌耐药性和进行临床治疗有重要指导意义。文章概述了当前细菌的多药耐药外排泵的主要分类和分布、结构特征、作用机制及表达调控等方面,阐明了多药耐药外排泵抑制剂的研究意义和价值,并对其研究前景进行展望。 展开更多
关键词 细菌 外排 抗生素 外排抑制
原文传递
A new look at anti-Helicobacter pylori therapy 被引量:22
3
作者 Seng-Kee Chuah Feng-Woei Tsay +1 位作者 Ping-I Hsu Deng-Chyang Wu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第35期3971-3975,共5页
With the rising prevalence of antimicrobial resistance,the treatment success of standard triple therapy has recently declined to unacceptable levels (i.e.,80% or less) in most countries.Therefore,several treatment reg... With the rising prevalence of antimicrobial resistance,the treatment success of standard triple therapy has recently declined to unacceptable levels (i.e.,80% or less) in most countries.Therefore,several treatment regimens have emerged to cure Helicobacter pylori (H.pylori) infection.Novel first-line anti-H.pylori therapies in 2011 include sequential therapy,concomitant quadruple therapy,hybrid (dual-concomitant) therapy and bismuth-containing quadruple therapy.After the failure of standard triple therapy,a bismuth-containing quadruple therapy comprising a proton pump inhibitor (PPI),bismuth,tetracycline and metronidazole can be employed as rescue treatment.Recently,triple therapy combining a PPI,levofloxacin and amoxicillin has been proposed as an alternative to the standard rescue therapy.This salvage regimen can achieve a higher eradication rate than bismuth-containing quadruple therapy in some regions and has less adverse effects.The best second-line therapy for patients who fail to eradicate H.pylori with first-line therapies containing clarithromycin,amoxicillin and metronidazole is unclear.However,a levofloxacin-based triple therapy is an accepted rescue treatment.Most guidelines suggest that patients requiring third-line therapy should be referred to a medical center and treated according to the antibiotic susceptibility test.Nonetheless,an empirical therapy (such as levofloxacin-based or furazolidone-based therapies) can be employed to terminate H.pylori infection if antimicrobial sensitivity data are unavailable. 展开更多
关键词 Bismuth-containing quadruple therapy Concomitant quadruple therapy Hybrid (dual-concomitant) therapy Rescue anti-Helicobacter pylori treatment Sequential therapy
下载PDF
KL-0153, a novel inhibitor of Pseudomonas aeruginosa MexAB-OprM efflux pump
4
作者 刘忆霜 王颖 +4 位作者 郑佳音 李兴华 关艳 黄树超 肖春玲 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2016年第4期310-315,共6页
Pseudomonas aeruginosa is an opportunistic pathogen that contributes to high morbidity and mortality. MexAB-OprM is the main efflux pump among the Resistance-Nodulation-Division family multi-drug effiux systems, which... Pseudomonas aeruginosa is an opportunistic pathogen that contributes to high morbidity and mortality. MexAB-OprM is the main efflux pump among the Resistance-Nodulation-Division family multi-drug effiux systems, which contribute greatly to the multidrug resistance of P. aeruginosa. Effiux pump inhibitors (EPIs) of MexAB-OprM could enhance the activity of the antibiotics effiuxed by MexAB-OprM, and thus they might be useful in the clinic as antibacterial synergistic agents. In this work, a new EPI of MexAB-OprM, KL-0153, was discovered by screening of a small molecular library. Its inhibition of MexAB-OprM was confirmed by assays of synergistic activity and EB accumulation. The activity of KL-0153 was shown to be synergistic with antibiotics effiuxed by MexAB-OprM when they were tested against strains expressing MexAB-OprM, especially so for the strains that express MexAB-OprM at high levels. KL-0153 showed more activity than the positive drug carbonyl cyanide m-chlorophenylhydrazone in the EB accumulation assay. It cannot be neglected that KL-0153 has significant liver and kidney toxicity. However, KL-0153 may be a lead comoound for the research and development of new tvoes of EPIs. 展开更多
关键词 Pseudomonas aeruginosa Multi-drug resistance Effiux pump MEXAB-OPRM INHIBITOR Antibacterial drug synergistic agent
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部